For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news. Researchers are testing a new oral, small-molecule GLP-1 receptor agonist ...

Bitcoin slips below $70,000 as rising losses, exchange inflows and extreme fear signal a renewed distribution phase. Bitcoin (BTC) sellers took control during the European trading session on Tuesday ...

Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug retatrutide, showing that participants on the highest dose lost an average of 70.3 ...

Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing ...

Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...

Retatrutide, Eli Lilly’s first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the TRIUMPH-1 phase 3 trial. Retatrutide is an investigational, ...

Sign up for the Concord Monitor’s morning newsletter for essential news each day, and our contests and promotions list for special offers and giveaways. Two years ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Structure Therapeutics said Monday that its ...

I can't stand opening the Microsoft Store. It's slow to load, confusing to browse, and full of ads for things I don't care about. Luckily, thanks to a new feature, I don't have to open the Microsoft ...